Adding diverse noncanonical backbones to rosetta: enabling peptidomimetic design. 2013

Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
Department of Biology, Center for Genomics and Systems Biology, New York University, New York, New York, USA.

Peptidomimetics are classes of molecules that mimic structural and functional attributes of polypeptides. Peptidomimetic oligomers can frequently be synthesized using efficient solid phase synthesis procedures similar to peptide synthesis. Conformationally ordered peptidomimetic oligomers are finding broad applications for molecular recognition and for inhibiting protein-protein interactions. One critical limitation is the limited set of design tools for identifying oligomer sequences that can adopt desired conformations. Here, we present expansions to the ROSETTA platform that enable structure prediction and design of five non-peptidic oligomer scaffolds (noncanonical backbones), oligooxopiperazines, oligo-peptoids, [Formula: see text]-peptides, hydrogen bond surrogate helices and oligosaccharides. This work is complementary to prior additions to model noncanonical protein side chains in ROSETTA. The main purpose of our manuscript is to give a detailed description to current and future developers of how each of these noncanonical backbones was implemented. Furthermore, we provide a general outline for implementation of new backbone types not discussed here. To illustrate the utility of this approach, we describe the first tests of the ROSETTA molecular mechanics energy function in the context of oligooxopiperazines, using quantum mechanical calculations as comparison points, scanning through backbone and side chain torsion angles for a model peptidomimetic. Finally, as an example of a novel design application, we describe the automated design of an oligooxopiperazine that inhibits the p53-MDM2 protein-protein interaction. For the general biological and bioengineering community, several noncanonical backbones have been incorporated into web applications that allow users to freely and rapidly test the presented protocols (http://rosie.rosettacommons.org). This work helps address the peptidomimetic community's need for an automated and expandable modeling tool for noncanonical backbones.

UI MeSH Term Description Entries
D000465 Algorithms A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. Algorithm
D012984 Software Sequential operating programs and data which instruct the functioning of a digital computer. Computer Programs,Computer Software,Open Source Software,Software Engineering,Software Tools,Computer Applications Software,Computer Programs and Programming,Computer Software Applications,Application, Computer Software,Applications Software, Computer,Applications Softwares, Computer,Applications, Computer Software,Computer Applications Softwares,Computer Program,Computer Software Application,Engineering, Software,Open Source Softwares,Program, Computer,Programs, Computer,Software Application, Computer,Software Applications, Computer,Software Tool,Software, Computer,Software, Computer Applications,Software, Open Source,Softwares, Computer Applications,Softwares, Open Source,Source Software, Open,Source Softwares, Open,Tool, Software,Tools, Software
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering
D017434 Protein Structure, Tertiary The level of protein structure in which combinations of secondary protein structures (ALPHA HELICES; BETA SHEETS; loop regions, and AMINO ACID MOTIFS) pack together to form folded shapes. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Tertiary Protein Structure,Protein Structures, Tertiary,Tertiary Protein Structures
D057786 Peptidomimetics Compounds that are designed to mimic the 3D structure of a natural peptide or protein. Peptidomimetic
D019295 Computational Biology A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories for solving biological problems including manipulation of models and datasets. Bioinformatics,Molecular Biology, Computational,Bio-Informatics,Biology, Computational,Computational Molecular Biology,Bio Informatics,Bio-Informatic,Bioinformatic,Biologies, Computational Molecular,Biology, Computational Molecular,Computational Molecular Biologies,Molecular Biologies, Computational

Related Publications

Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
January 2012, PloS one,
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
August 1998, Current opinion in chemical biology,
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
January 2016, Methods in molecular biology (Clifton, N.J.),
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
March 2016, Nature chemical biology,
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
May 2018, Chemical communications (Cambridge, England),
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
February 2021, The Journal of chemical physics,
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
June 2014, Organic letters,
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
January 2016, Methods in molecular biology (Clifton, N.J.),
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
June 2006, Journal of medicinal chemistry,
Kevin Drew, and P Douglas Renfrew, and Timothy W Craven, and Glenn L Butterfoss, and Fang-Chieh Chou, and Sergey Lyskov, and Brooke N Bullock, and Andrew Watkins, and Jason W Labonte, and Michael Pacella, and Krishna Praneeth Kilambi, and Andrew Leaver-Fay, and Brian Kuhlman, and Jeffrey J Gray, and Philip Bradley, and Kent Kirshenbaum, and Paramjit S Arora, and Rhiju Das, and Richard Bonneau
January 2024, Protein engineering, design & selection : PEDS,
Copied contents to your clipboard!